S&P 500   4,539.17 (-0.25%)
DOW   35,656.13 (+0.64%)
QQQ   386.72 (-0.79%)
AAPL   188.58 (-0.42%)
MSFT   376.85 (-0.53%)
META   323.52 (-2.61%)
GOOGL   132.15 (-2.10%)
AMZN   145.18 (-0.78%)
TSLA   239.92 (-1.73%)
NVDA   467.16 (-2.96%)
NIO   7.21 (+0.42%)
BABA   74.31 (-0.48%)
AMD   120.20 (-2.95%)
T   16.47 (+1.04%)
F   10.32 (-2.55%)
MU   75.93 (-0.99%)
CGC   0.55 (-1.72%)
GE   120.60 (+1.46%)
DIS   92.62 (+0.13%)
AMC   6.85 (-4.46%)
PFE   30.43 (+1.16%)
PYPL   57.32 (-1.12%)
XOM   102.12 (-0.21%)
S&P 500   4,539.17 (-0.25%)
DOW   35,656.13 (+0.64%)
QQQ   386.72 (-0.79%)
AAPL   188.58 (-0.42%)
MSFT   376.85 (-0.53%)
META   323.52 (-2.61%)
GOOGL   132.15 (-2.10%)
AMZN   145.18 (-0.78%)
TSLA   239.92 (-1.73%)
NVDA   467.16 (-2.96%)
NIO   7.21 (+0.42%)
BABA   74.31 (-0.48%)
AMD   120.20 (-2.95%)
T   16.47 (+1.04%)
F   10.32 (-2.55%)
MU   75.93 (-0.99%)
CGC   0.55 (-1.72%)
GE   120.60 (+1.46%)
DIS   92.62 (+0.13%)
AMC   6.85 (-4.46%)
PFE   30.43 (+1.16%)
PYPL   57.32 (-1.12%)
XOM   102.12 (-0.21%)
S&P 500   4,539.17 (-0.25%)
DOW   35,656.13 (+0.64%)
QQQ   386.72 (-0.79%)
AAPL   188.58 (-0.42%)
MSFT   376.85 (-0.53%)
META   323.52 (-2.61%)
GOOGL   132.15 (-2.10%)
AMZN   145.18 (-0.78%)
TSLA   239.92 (-1.73%)
NVDA   467.16 (-2.96%)
NIO   7.21 (+0.42%)
BABA   74.31 (-0.48%)
AMD   120.20 (-2.95%)
T   16.47 (+1.04%)
F   10.32 (-2.55%)
MU   75.93 (-0.99%)
CGC   0.55 (-1.72%)
GE   120.60 (+1.46%)
DIS   92.62 (+0.13%)
AMC   6.85 (-4.46%)
PFE   30.43 (+1.16%)
PYPL   57.32 (-1.12%)
XOM   102.12 (-0.21%)
S&P 500   4,539.17 (-0.25%)
DOW   35,656.13 (+0.64%)
QQQ   386.72 (-0.79%)
AAPL   188.58 (-0.42%)
MSFT   376.85 (-0.53%)
META   323.52 (-2.61%)
GOOGL   132.15 (-2.10%)
AMZN   145.18 (-0.78%)
TSLA   239.92 (-1.73%)
NVDA   467.16 (-2.96%)
NIO   7.21 (+0.42%)
BABA   74.31 (-0.48%)
AMD   120.20 (-2.95%)
T   16.47 (+1.04%)
F   10.32 (-2.55%)
MU   75.93 (-0.99%)
CGC   0.55 (-1.72%)
GE   120.60 (+1.46%)
DIS   92.62 (+0.13%)
AMC   6.85 (-4.46%)
PFE   30.43 (+1.16%)
PYPL   57.32 (-1.12%)
XOM   102.12 (-0.21%)

U.S. Stem Cell Stock Price, News & Analysis (OTCMKTS:USRM)

Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
$70,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

USRM stock logo

About U.S. Stem Cell Stock (OTCMKTS:USRM)

U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.


USRM Stock News Headlines

The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Has Anyone had Stem Cell treatment
NIH announces owners of stem cells
Thompson: Stem cell lines 'viable for research'
See More Headlines
Receive USRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for U.S. Stem Cell and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/07/2019
Today
11/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:USRM
Previous Symbol
NASDAQ:BHRT
Employees
11
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
($0.02) per share

Miscellaneous

Free Float
550,903,000
Market Cap
$70,000.00
Optionable
Not Optionable
Beta
-0.75

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Michael Tomas (Age 57)
    CEO, President, CFO & Director
  • Dr. Colleen Robb
    Senior Compliance Officer
  • Mr. Phil Posa
    Senior Vice President of U.S. & International Sales
  • Ms. Evelyn Flores
    Corporate Controller
  • Dr. Sergio Pinski
    Medical Director & Member of Scientific Advisory Board














USRM Stock Analysis - Frequently Asked Questions

How were U.S. Stem Cell's earnings last quarter?

U.S. Stem Cell, Inc. (OTCMKTS:USRM) issued its earnings results on Wednesday, August, 7th. The company reported $0.00 EPS for the quarter. The firm had revenue of $1.30 million for the quarter.

What other stocks do shareholders of U.S. Stem Cell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other U.S. Stem Cell investors own include Orion Energy Systems (OESX), Actinium Pharmaceuticals (ATNM), Cleveland BioLabs (CBLI), Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX), Axsome Therapeutics (AXSM) and

How do I buy shares of U.S. Stem Cell?

Shares of USRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:USRM) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -